Beta Bionics, Inc. Common Stock (BBNX)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $892.71M
Last updated: Nov 17, 2026 at 11:05 AM ET
Beta Bionics, Inc. Common Stock (BBNX) Earnings: Report Dates and Results
Beta Bionics, Inc. Common Stock (BBNX) is expected to report earnings on Feb 15, 2027. In the quarter ended Sep 30, 2026, Beta Bionics, Inc. Common Stock reported EPS of -$0.52, above the -$0.53 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
BBNX has an expected report date of Feb 15, 2027.
BBNX Earnings Call
The latest BBNX earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 8 quarters below that had an estimate, BBNX beat 6 and missed 2. Revenue for the quarter ended Sep 30, 2026 was $35.51M, up 30.3% from $27.25M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.52 | -$0.53 | -$0.55 - -$0.46 | +1.89% | Beat | N/A | 3 | 1 up, 0 down | Oct 27, 2026 | $35.51M |
| Jun 30, 2026 | -$0.53 | -$0.62 | -$0.66 - -$0.46 | +14.52% | Beat | N/A | 2 | 0 up, 1 down | Jul 29, 2026 | $32.01M |
| Mar 31, 2026 | -$0.36 | -$0.45 | -$0.52 - -$0.36 | +20.00% | Beat | N/A | 5 | 2 up, 2 down | Apr 21, 2026 | $27.63M |
| Dec 31, 2025 | -$0.30 | -$0.38 | -$0.48 - -$0.28 | +21.05% | Beat | N/A | 9 | 1 up, 0 down | Feb 17, 2026 | $32.12M |
| Sep 30, 2025 | -$0.33 | -$0.41 | N/A | +19.51% | Beat | N/A | N/A | N/A | Oct 28, 2025 | $27.25M |
| Jun 30, 2025 | -$0.27 | -$0.47 | N/A | +42.55% | Beat | N/A | N/A | N/A | Jul 29, 2025 | $23.24M |
| Mar 31, 2025 | -$0.93 | -$0.51 | N/A | -82.35% | Miss | N/A | N/A | N/A | May 6, 2025 | $17.64M |
| Dec 31, 2024 | -$2.72 | -$1.22 | N/A | -123.56% | Miss | N/A | N/A | N/A | Jan 31, 2025 | $20.44M |
| Sep 30, 2024 | -$0.82 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 27, 2024 | $16.70M |
Annual EPS
| Fiscal year ended | EPS | Change |
|---|---|---|
| Sep 30, 2026 | -$1.41 | N/A |
| Jun 30, 2026 | -$0.89 | N/A |
| Dec 31, 2025 | -$1.83 | N/A |
| Jun 30, 2025 | -$1.05 | N/A |
| Dec 31, 2024 | -$3.54 | N/A |
Earnings Calls
The 7 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,100 words across 16 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 9,069 | 16 | |
| 2026Q2 | Jun 30, 2026 | 5,816 | 15 | |
| 2026Q1 | Mar 31, 2026 | 7,573 | 15 | |
| 2025Q4 | Dec 31, 2025 | 9,538 | 17 | |
| 2025Q3 | Sep 30, 2025 | 8,089 | 14 | |
| 2025Q2 | Jun 30, 2025 | 8,774 | 12 | |
| 2025Q1 | Mar 31, 2025 | 9,064 | 11 |
2026Q3 Earnings Call
Opening remarks
Blake Beber Head of Investor Relations Good afternoon, and thank you for joining Beta Bionics' third quarter 2026 earnings call. With me on today's call are Chief Executive Officer Sean Saint and Chief Financial Officer Stephen Feider. Both the replay of this call and the press release discussing our third quarter 2026 results will be available on the Investor Relations section of our website. Information recorded on this call speaks only as of today, October 27, 2026. If you are listening to a replay of this call, any time-sensitive information may no longer be accurate. Also on our website are our supplemental third quarter 2026 earnings presentation and updated corporate presentation. We encourage you to refer to those documents for a summary of key metrics and business updates. Before we begin, we'd like to remind you that today's discussion will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements reflect management's expectations about future events, our product pipeline, development timelines, financial performance, and operating plans, and speak only as of today's date. Please refer to the cautionary statements in the press release we issued earlier today for a detailed explanation of the inherent limitations of such forward-looking statements. These documents contain and identify important factors that may cause actual results to differ materially from current expectations expressed or implied by our forward-looking statements. We undertake no obligation to update them to reflect subsequent events or circumstances except to the extent required by law. With that, I'd now like to hand the call over to Sean.
Sean Saint CEO Thanks, Blake, and thanks, everyone, for joining. Q3 is usually a somewhat boring quarter in diabetes, with summer vacations and a lull of news after ADA. Today, we're going to do our best to spice it up a little bit with some great updates. So let's dive in. In September, we received FDA clearance for Mint, our transformative patch pump, which we expect to fully commercialize in the U.S. in Q1 of 2027. I feel this will ultimately prove to be the largest milestone achieved by the company to this point, and what an incredible effort it has been from the team to get that product designed, developed, and cleared by the FDA in a matter of about three years, which we believe is the fastest-ever timeline from concept to clearance for an automated insulin delivery, or AID, patch pump. We believe that Mint will be a game changer for people with diabetes. Starting in Q1 of next year, the only fully adaptive and most advanced insulin dosing algorithm in the U.S.
Frequently Asked Questions About BBNX
When is Beta Bionics, Inc. Common Stock's next earnings date?
Beta Bionics, Inc. Common Stock's next earnings report is expected for Feb 15, 2027.
Did BBNX beat earnings estimates last quarter?
Yes. Beta Bionics, Inc. Common Stock reported EPS of -$0.52 for the quarter ended Sep 30, 2026, above the -$0.53 estimate, a 1.89% surprise.
What EPS do analysts expect from BBNX next quarter?
The consensus EPS estimate for Beta Bionics, Inc. Common Stock for the quarter ending Dec 31, 2026 is -$0.51 from 16 analysts, with estimates from -$0.62 to -$0.45.
How often does BBNX beat earnings estimates?
Beta Bionics, Inc. Common Stock beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of -10.80%.
BBNX pages: Overview, Earnings, Forecast, Financials, Competitors